International Vaccine Institute, Seoul, Republic of Korea.
Research & Collaboration, Anka Analytica, Melbourne, Australia.
Clin Infect Dis. 2023 Dec 20;77(Suppl 7):S519-S527. doi: 10.1093/cid/ciad585.
An effective implementation of antimicrobial resistance (AMR) surveillance projects requires sustainable and multidisciplinary engagement with stakeholders from various backgrounds, interests and aims. The "Capturing Data on Antimicrobial resistance Patterns and Trends in Use in Regions of Asia" (CAPTURA) project, funded by the Fleming Fund, initially targeted 12 countries in South Asia (SA) and Southeast Asia (SEA) to "expand the volume of historical and current data on AMR and antimicrobial usage" and support local agencies through capacity building activities.
In this article, we focus on early stakeholder engagement activities and present overall statistics on AMR data collated from 72 laboratories across seven countries. This included 2.3 million records of antimicrobial susceptibility testing (AST) data, which were curated, analyzed, and shared back to the facilities for informed decision making.
Approximately 98% of the data collated by CAPTURA originated from laboratories based in SA countries. Furthermore, country-wide data were analyzed to identify commonly reported pathogens in each country, followed by descriptions of AST practices and multidrug-resistant (MDR) pathogens. Overall, we found meager adherence to standard guidelines to perform and record AST results, and a significant number of MDR pathogens were reported.
We conclude that close collaboration with the existing national mechanisms for identifying AMR data sources was crucial for the project's success. Although we show a vast retrospective dataset on AMR is available for data sharing in Asia, there remain critical gaps in data generation/management practice and analysis capacity for AMR data at most facilities.
有效的抗菌药物耐药性（AMR）监测项目的实施需要与来自不同背景、利益和目标的利益相关者进行可持续和多学科的合作。由 Fleming 基金资助的“亚洲地区抗菌药物耐药模式和趋势数据收集（CAPTURA）”项目最初针对南亚（SA）和东南亚（SEA）的 12 个国家，旨在“扩大 AMR 和抗菌药物使用的历史和当前数据量”，并通过能力建设活动支持当地机构。
在本文中，我们重点介绍早期的利益相关者参与活动，并展示了从七个国家的 72 个实验室收集的 AMR 数据的总体统计数据。这包括 230 万份抗菌药物敏感性测试（AST）数据记录，这些数据经过整理、分析并反馈给实验室，以便做出明智的决策。
CAPTURA 收集的数据中约有 98%来自 SA 国家的实验室。此外，对全国范围内的数据进行了分析，以确定每个国家常见的报告病原体，然后描述 AST 实践和多药耐药（MDR）病原体。总体而言，我们发现执行和记录 AST 结果的标准指南遵循率很低，并且报告了大量的 MDR 病原体。
我们的结论是，与现有的国家 AMR 数据来源识别机制密切合作对项目的成功至关重要。虽然我们展示了亚洲地区可用于数据共享的大量 AMR 回溯数据集，但大多数实验室在数据生成/管理实践和 AMR 数据分析能力方面仍存在关键差距。
